Earnings Summary

Xenon Pharmaceuticals Inc’s net profit fell -29.57% since last year same period to $-62.79Mn in the Q3 2024. On a quarterly growth basis, Xenon Pharmaceuticals Inc has generated -8.4% fall in its net profits since last 3-months.

Xenon Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.81 - a -15.71% fall from last quarter’s estimates.

Xenon Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.81.

Xenon Pharmaceuticals Inc’s earning per share (EPS) fell -10.96% since last year same period to -0.81 in the Q3 2024. This indicates that the Xenon Pharmaceuticals Inc has generated -10.96% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Xenon Pharmaceuticals Inc’s return on assets (ROA) stands at -0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Xenon Pharmaceuticals Inc’s return on equity (ROE) stands at -0.27.